Paracrine inhibition of osteoblast differentiation induced by neuroblastoma cells
暂无分享,去创建一个
Nicola Baldini | Armando Giunti | N. Baldini | S. R. Baglio | A. Giunti | D. Granchi | I. Amato | Donatella Granchi | Serena Rubina Baglìo | Ilaria Amato
[1] D. Prockop,et al. The Wnt Signaling Inhibitor Dickkopf-1 Is Required for Reentry into the Cell Cycle of Human Adult Stem Cells from Bone Marrow* , 2003, Journal of Biological Chemistry.
[2] N. Baldini,et al. Plasma levels of receptor activator of nuclear factor‐κB ligand and osteoprotegerin in patients with neuroblastoma , 2006, International journal of cancer.
[3] S. Bruder,et al. Growth kinetics, self‐renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation , 1997, Journal of cellular biochemistry.
[4] Hartmut Goldschmidt,et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.
[5] A. Donfrancesco,et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] B. Riggs,et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. , 2000, Endocrinology.
[7] D. Prockop,et al. How Wnt Signaling Affects Bone Repair by Mesenchymal Stem Cells from the Bone Marrow , 2005, Annals of the New York Academy of Sciences.
[8] F. Zhan,et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. , 2003, The New England journal of medicine.
[9] B. Komm,et al. Wnt signaling and osteoblastogenesis , 2007, Reviews in Endocrine and Metabolic Disorders.
[10] S. Hettmer,et al. Low complex ganglioside expression characterizes human neuroblastoma cell lines. , 2005, Cancer letters.
[11] J. Chirgwin,et al. Basic Mechanisms Responsible for Osteolytic and Osteoblastic Bone Metastases , 2006, Clinical Cancer Research.
[12] H. Shimada,et al. Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. , 2005, Cancer research.
[13] Jindrich Cinatl,et al. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. , 2006, International journal of oncology.
[14] O. Sezer,et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. , 2005, Biochemical and biophysical research communications.
[15] L. Papucci,et al. In vitro blockade of receptor activator of nuclear factor‐κB ligand prevents osteoclastogenesis induced by neuroblastoma cells , 2004, International journal of cancer.
[16] Chiara Brignole,et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. , 2006, Journal of the National Cancer Institute.
[17] K. Neville,et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Hans Clevers,et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.
[19] P. Schiller,et al. Age‐Related Osteogenic Potential of Mesenchymal Stromal Stem Cells from Human Vertebral Bone Marrow , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[20] Roland Baron,et al. BMP‐2 Controls Alkaline Phosphatase Expression and Osteoblast Mineralization by a Wnt Autocrine Loop , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] R. Marchelli,et al. Anti-gene peptide nucleic acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth inhibition and apoptosis , 2005, Molecular Cancer Therapeutics.
[22] J. Chirgwin,et al. Meeting report from skeletal complications of malignancy IV , 2006 .
[23] Brendan F Boyce,et al. Biology of RANK, RANKL, and osteoprotegerin , 2007, Arthritis research & therapy.
[24] H. Shimada,et al. Mechanisms of bone invasion and metastasis in human neuroblastoma. , 2005, Cancer letters.
[25] K. Ozono,et al. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. , 2001, Cancer research.
[26] A. Yang,et al. Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.
[27] S. Janz,et al. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF , 2007, Molecular Cancer.
[28] C. Crews,et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. , 2003, The Journal of clinical investigation.
[29] J. Adams. Development of the proteasome inhibitor PS-341. , 2002, The oncologist.
[30] Ivan Lobov,et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.